核心观点 - Alterity Therapeutics (ATHE) 的股价在7月17日上涨7.8%，原因是公司公布了其主要候选药物ATH434在治疗多系统萎缩(MSA)的II期ATH434-202研究中的积极中期数据 [1] 公司动态 - 公司公布了ATH434-202研究的积极中期数据，该研究评估了ATH434在治疗多系统萎缩(MSA)患者中的效果，研究招募了10名晚期MSA患者 [1] - 中期分析结果包括来自7名接受ATH434治疗6个月的参与者的临床和生物标志物数据，以及来自3名接受ATH434治疗12个月的参与者的神经影像数据 [1] - 数据显示，43%的参与者在统一MSA评分量表第一部分(UMSARS1)上显示出改善，表明在治疗6个月后日常活动能力有所提高，29%的参与者在同一时间点表现出神经系统症状的稳定或改善 [1] - 患者在接受ATH434治疗后表现出有利的临床和生物标志物结果，这表明ATH434有可能改变MSA治疗的过程 [2] - 公司目前正在进行两个中期研究，除了ATH434-202研究外，还有评估ATH434在早期MSA中的II期ATH434-201研究 [2] - ATH434是一种口服候选药物，旨在抑制与神经退行性变相关的病理蛋白的聚集 [2] - ATH434已被FDA和欧洲药品管理局授予治疗MSA适应症的孤儿药称号 [3] - 公司预计在2025年上半年公布ATH434-202研究的最终12个月数据 [2] 行业表现 - Alterity的股价今年迄今已下跌14.2%，而行业整体下跌1% [2] 其他公司信息 - Alterity目前持有Zacks排名3(持有) [4] - 在生物技术领域，一些排名靠前的公司包括Entrada Therapeutics, Inc. (TRDA)、Compugen Ltd. (CGEN)和Beyond Air, Inc. (XAIR)，它们目前都持有Zacks排名1(强力买入) [4] - 在过去60天内，Entrada Therapeutics的2024年每股亏损预测从14美分收窄至13美分，2025年每股亏损预测从3.44美元收窄至3.21美元，TRDA的股价今年迄今已上涨13.4% [4] - Compugen的2024年每股收益预测在过去60天内从2美分提高到5美分，而2025年每股亏损预测从27美分收窄至11美分，CGEN的股价今年迄今已下跌6% [4] - Beyond Air的2024年每股亏损预测在过去60天内从44美分收窄至35美分，2025年每股亏损预测从1.45美元收窄至1.01美元，XAIR的股价今年迄今已下跌71.4% [5]

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease ...

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease ...

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease ...

文章核心观点 - 公司Alterity Therapeutics是一家专注于开发治疗神经退行性疾病的临床阶段生物技术公司 [4] - 公司的主要资产ATH434有潜力治疗帕金森综合征相关疾病,目前正在进行两项II期临床试验 [4] - 公司还拥有广泛的药物发现平台,可以产生可专利的化合物来治疗神经系统疾病的基础病理 [4] 公司概况 - 公司总部位于澳大利亚墨尔本和美国旧金山 [4] - 公司首席执行官David Stamler博士将在MST Access "生命科学隐藏的宝石"网络研讨会上发表公司概况 [1][2] - 网络研讨会将于2024年6月13日在澳大利亚和6月12日在美国举行 [2] - 研讨会结束后将在公司网站上提供录像 [3] 投资者和媒体联系人 - 澳大利亚联系人:Hannah Howlett [6] - 美国联系人:Remy Bernarda [7]

MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States. Details a ...

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 20 ...

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 20 ...

 - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase ...

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA. The poster, ...